The prognostic factors for patients with glioblastoma multiforme

.SUMMARYIntroduction: Glioblastoma multiforme is the most common and the mostmalignant kind of glioma and median survival time is less than one year. Age,performance status, mental status, grade and histology of tumor, extent ofresection, hypovascularity, presence of seizures, duration of synptoms,chemotherapy and radiotherapy have been reported as the prognostic factorsfor survival. In this study we aimed to evaluate the factors influencing onsurvival of the patients with glioblastoma multiforme retropectively.Materials and Methods: The patients with the diagnosis of glioblastomamultiforme who received surgery, radiotherapy or chemotherapy betweenJanuary 1999 and June 2012 were included in this study. A total of 137 patients?clinical records, radiological records, management modalities, clinical coursesand toxicities developed during tretment were evaluated retrospectively.Kaplan-Meier survival analysis and Cox regression analysis were used to findthe factors independently influencing patients? overall survival time.Results: Median overall survival for our patients was 62 (%95 CI; 51.05-72.95)weeks. Age, preoperative Karnofsky Performance Scale (KPS) score, tumorresection extent, maximal tumor diameter, steroid use, persistant hyperglycemiaand adjuvant temozolomide therapy were statistically significant factors (P<0.05) for OS in the univariate analysis. Cox proportional hazards modelingrevealed that age ?50 years, preoperative KPS score ?70, absence ofpersistant hyperglycemia and adjuvant temozolomide treatment more than 3cycles were independent favorable factors (P <0.05) for patients clinicaloutcomes.Conclusion: Age at diagnosis, preoperative performance status, persistanthyperglycemia and adjuvant temozolomide therapy were the significant factorsthat correlate with prognosis.